CV Sciences (CVSI) Change in Accured Expenses (2011 - 2026)
CV Sciences (CVSI) posted Change in Accured Expenses of $92000.0 for Q1 2026, up 134.59% sequentially from -$266000.0 in Q4 2025, and up 118.93% YoY from $42022.6 in Q1 2025.
CV Sciences (CVSI) Change in Accured Expenses (2011 - 2026) Analysis & Trends
CV Sciences has reported Change in Accured Expenses for 16 years, with the latest figure at $92000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 118.93% year-over-year to $92000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$764000.0 (up 14.83% YoY) and the FY2025 annual result came in at -$1.3 million, down 187.37% from the prior year.
- Change in Accured Expenses improved to $92000.0 in Q1 2026 per CVSI's latest filing, from -$266000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $193000.0 in Q3 2023 and troughed at -$563000.0 in Q3 2025.
- A 5-year average of -$193352.9 and a median of -$187000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 144.37% in 2023, down 1155.0% in 2023.
- Over 5 years, Change in Accured Expenses stood at -$20000.0 in 2022, then plunged by 1155.0% to -$251000.0 in 2023, then jumped by 141.04% to $103000.0 in 2024, then plunged by 358.25% to -$266000.0 in 2025, then soared by 134.59% to $92000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $92000.0, -$266000.0, and -$563000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 85,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85,000.00 |
| Jun 30, 2026 | 85,000.00 |
| Mar 31, 2026 | 92,000.00 |
| Mar 31, 2026 | 92,000.00 |
| Dec 31, 2025 | -266,000.00 |
| Dec 31, 2025 | -266,000.00 |
| Sep 30, 2025 | -563,000.00 |
| Sep 30, 2025 | -563,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | -486,000.00 |
| Mar 31, 2025 | -486,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | -327,000.00 |
| Sep 30, 2024 | -327,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | -56,000.00 |
| Mar 31, 2024 | -56,000.00 |